CTOs on the Move


 
MiraMed Global Services stands as the premier global provider of business process outsourcing solutions to healthcare organizations nationwide. MiraMed partners with hospitals, health networks, physician practices and related industry service organizations to provide a broad portfolio of customizable solutions, uncover and capitalize on hidden financial opportunities, improve productivity and ultimately increase profits. The key to MiraMed`s success is its unique business model that has evolved over the last twenty-five years. Under this model, MiraMed pairs healthcare industry experts with world-class processes, infrastructure and technology to deliver meaningful and measurable results. This proprietary model enables sustainable change by delivering a complete, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.miramedgs.com
  • 255 West Michigan Avenue
    Jackson, MI USA 49201
  • Phone: 866.544.6647

Executives

Name Title Contact Details

Similar Companies

Educational Concepts in Medicine

Educational Concepts in Medicine is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Simplexity Health

Simplexity Health is a Klamath Falls, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Essential Group

Essential Group, Inc is a Gurnee, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New West Health Services

At New West, we believe it makes more sense to help you stay healthy rather than just caring for you after you've become sick or injured. That's why we've developed a full line of products to give you the best choice in group and individual health care

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.